Artelo Biosciences (ARTL) announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Spring had been serving as a financial consultant to the Company since December 2024.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Enters Cooperation Agreement with Farb
- Artelo announces expanded clinical data to be presented on ART26.12, ART27.13
- Artelo prices 441,210 shares at $4.40 in underwritten public offering
- Artelo Biosciences files to sell common stock, no amount given
- Artelo Biosciences presents interim Phase 2 CAReS data on ART27.13